TiumBio
티움바이오 · 321550
Health Care Biotechnology · KOSDAQ
Market cap US$135M (₩186.2B)
Overview
TiumBio is a South Korean biotech company, listed on KOSDAQ, that researches and develops treatments for rare and hard-to-treat diseases.
It works across two drug-discovery approaches, small-molecule synthetic drugs and biologic drugs, selecting whichever method best suits the disease target. The company's pipeline is aimed at patients and healthcare systems that need therapies for conditions with limited existing options.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$3.5M
- FY2024US$4.9M
- FY2025US$8.9M
Operating profit
- FY2023−US$20.2M
- FY2024−US$13.6M
- FY2025−US$11.7M
Net income
- FY2023−US$13.8M
- FY2024−US$17.1M
- FY2025−US$13.6M
Key ratios (FY2025)
Why it matters
TiumBio was founded by the chief executive and core researchers who previously developed the hemophilia biologic Afstyla at SK Chemicals and completed a technology-licensing deal for it.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?